Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 31 to 34 of 34 results for adalimumab psoriasis

  1. Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors (TA407)

    Evidence-based recommendations on secukinumab (Cosentyx) for treating active ankylosing spondylitis that has not responded well enough to conventional therapy.

    Technology appraisal guidance
    Published
    28 September 2016
    View recommendations

    Sections for TA407

  2. Apremilast for treating active psoriatic arthritis (TA433)

    Evidence-based recommendations on apremilast (Otezla) for treating active psoriatic arthritis.

    Technology appraisal guidance
    Published
    22 February 2017
    View recommendations

    Sections for TA433

  3. Trials that evaluate utility values (using generic preference-based measures) in children and young people with severe psoriasis are needed to better inform future cost–utility analyses.

    generic preference-based measures) in children and young people with severe psoriasis are needed to better inform future cost–utility...

    Research recommendation
    Published
    15 October 2018

  4. Past appeals and decisions

    Past technology appraisal appeals and decisions